Cue Biopharma News

Cue Biopharma (CUE.US): The 2024 Q1 financial report achieved revenue of US$1,717,000, with a previous value of US$187,000 and an expected value of US$1.21 million; earnings per share were -0.25 dollars, the previous value was -0.29 dollars, and the expec

Cue Biopharma (CUE.US): The 2024 Q1 financial report achieved revenue of US$1,717,000, with a previous value of US$187,000 and an expected value of US$1.21 million; earnings per share were -0.25 dollars, the previous value was -0.29 dollars, and the expected value was -0.28 dollars.

Zhitong Finance07:20

Cue Biopharma Q1 2024 Adj EPS $(0.25) Beats $(0.28) Estimate

Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.28) by 10.71 percent.

Benzinga04:57

Cue Biopharma | 10-Q: Quarterly report

Futu News04:05 · Announcements

Cue Biopharma 1Q Loss $12.3M >CUE

Cue Biopharma 1Q Loss $12.3M >CUE

Dow Jones04:05

Cue Biopharma to Present at the 20th Annual PEGS Boston Summit

Stockhouse May 8 20:00

Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference

BOSTON, May 07, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disea

GlobeNewswireMay 7 20:00

Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T

GlobeNewswireApr 24 22:01

Here's Why Cue Biopharma (CUE) Is a Great 'Buy the Bottom' Stock Now

Yahoo FinanceApr 15 21:55

Cue Biopharma (CUE.US): The 2023 Q4 earnings report achieved revenue of $1,821,000, with an estimated value of $1.71 million; earnings per share were -0.28 US dollars, the previous value was -0.37 US dollars, and the expected value was -0.28 US dollars.

Cue Biopharma (CUE.US): The 2023 Q4 earnings report achieved revenue of $1,821,000, with an estimated value of $1.71 million; earnings per share were -0.28 US dollars, the previous value was -0.37 US dollars, and the expected value was -0.28 US dollars.

Zhitong FinanceApr 9 22:20

Forecasting The Future: 4 Analyst Projections For Cue Biopharma

Throughout the last three months, 4 analysts have evaluated Cue Biopharma (NASDAQ:CUE), offering a diverse set of opinions from bullish to bearish.The following table summarizes their recent ratings,

BenzingaApr 9 22:01

Cue Biopharma: A Strong Buy on Clinical Breakthroughs and Strategic Financial Positioning

TipRanksApr 9 21:35

Cue Biopharma Price Target Maintained With a $8.00/Share by Stifel

Cue Biopharma Price Target Maintained With a $8.00/Share by Stifel

Dow JonesApr 9 20:56

Oppenheimer: Maintaining the Cue Biopharma (CUE.US) rating, adjusted from superior to superior market ratings, and adjusted the target price from $10.00 to $10.00.

Oppenheimer: Maintaining the Cue Biopharma (CUE.US) rating, adjusted from superior to superior market ratings, and adjusted the target price from $10.00 to $10.00.

Zhitong FinanceApr 9 20:32

Oppenheimer Maintains Outperform on Cue Biopharma, Maintains $10 Price Target

Oppenheimer analyst Leland Gershell maintains Cue Biopharma (NASDAQ:CUE) with a Outperform and maintains $10 price target.

BenzingaApr 9 20:22

Oppenheimer Remains a Buy on Cue Biopharma (CUE)

TipRanksApr 9 19:35

Cue Biopharma (CUE) Gets a Buy From Stifel Nicolaus

TipRanksApr 9 19:07

Cue Biopharma Inc (CUE) Q4 2023 Earnings Call Transcript Highlights: Strategic Alliances and ...

Yahoo FinanceApr 9 15:02

Earnings Call Summary | Cue Biopharma(CUE.US) Q4 2023 Earnings Conference

The following is a summary of the Cue Biopharma, Inc. (CUE) Q4 2023 Earnings Call Transcript:Financial Performance:Cue Biopharma reported collaboration revenue of approximately $1.8 million in Q4, pri

Futu NewsApr 9 10:03 · Conference Call

Cue Biopharma Q1 EPS $(0.28) Misses $(0.27) Estimate, Sales $1.82M Beat $1.13M Estimate

Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.27) by 3.7 percent. This is a 3.45 percent increase over losses of $(0.29)

BenzingaApr 9 04:06

Press Release: Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights

Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights BOSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stag

Dow JonesApr 9 04:05